Abstract
Although it represents a composite of more than one clinical study, this work helps to define the potential of phentolamine in the management of erectile dysfunction (ED). The use of oral (buccal) phentolamine could represent a viable alternative to phospho diesterase (PDE) inhibitors or for use in sildenafil failures.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
15.1 Key Trial References
15.1.1 Major Publication
Goldstein I, Carson C, et al. Vasomax for the treatment of male erectile dysfunction. World J Urol 19:51–56, 2001.
15.1.2 Other Important Publications
Goldstein I. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. Int J Impot Res 12(suppl 1):S75–80, 2000.
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2007). Summary of Clinical Trials of Phentolamine. In: Key Clinical Trials in Erectile Dysfunction. Springer, London. https://doi.org/10.1007/978-1-84628-428-1_15
Download citation
DOI: https://doi.org/10.1007/978-1-84628-428-1_15
Publisher Name: Springer, London
Print ISBN: 978-1-84628-427-4
Online ISBN: 978-1-84628-428-1
eBook Packages: MedicineMedicine (R0)